tiprankstipranks
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
PremiumPress ReleasesAgios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2M ago
Agios Pharmaceuticals reports 2023 EPS ($6.33), consensus ($6.26)
PremiumThe Fly
Agios Pharmaceuticals reports 2023 EPS ($6.33), consensus ($6.26)
2M ago
AGIO Earnings this Week: How Will it Perform?
PremiumPre-Earnings
AGIO Earnings this Week: How Will it Perform?
2M ago
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
PremiumPress ReleasesAgios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
4M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
PremiumPress Releases
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
4M ago
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
PremiumPress ReleasesAgios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
5M ago
Agios announces clinical proof-of-concept Phase 2a trial of AG-946
PremiumThe Fly
Agios announces clinical proof-of-concept Phase 2a trial of AG-946
5M ago
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
PremiumPress Releases
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100